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Abstract Edoxaban is a once-daily oral anticoagulant that
rapidly and selectively inhibits factor Xa in a concentration-
dependent manner. This review describes the extensive
clinical development program of edoxaban, including phase
III studies in patients with non-valvular atrial fibrillation
(NVAF) and symptomatic venous thromboembolism (VTE).
The ENGAGE AF-TIMI 48 study (N = 21,105; mean
CHADS2 score 2.8) compared edoxaban 60 mg once daily
(high-dose regimen) and edoxaban 30 mg once daily (low-
dose regimen) with dose-adjusted warfarin [international
normalized ratio (INR) 2.0–3.0] and found that both regimens
were non-inferior to warfarin in the prevention of stroke and
systemic embolism in patients with NVAF. Both edoxaban
regimens also provided significant reductions in the risk of
hemorrhagic stroke, cardiovascular mortality, major bleed-
ing and intracranial bleeding. The Hokusai-VTE study
(N = 8,292) in patients with symptomatic VTE had a flexible
treatment duration of 3–12 months and found that following
initial heparin, edoxaban 60 mg once daily was non-inferior
to dose-adjusted warfarin (INR 2.0–3.0) for the prevention of
recurrent VTE, and also had a significantly lower risk of
bleeding events. Both studies randomized patients at mod-
erate-to-high risk of thromboembolic events and were further
designed to simulate routine clinical practice as much as
possible, with edoxaban dose reduction (halving dose) at
randomisation or during the study if required, a frequently
monitored and well-controlled warfarin group, a well-moni-
tored transition period at study end and a flexible treatment
duration in Hokusai-VTE. Given the phase III results
obtained, once-daily edoxaban may soon be a key addition to
the range of antithrombotic treatment options.
Key Points
Pivotal phase III studies with edoxaban, a rapid,
selective, once-daily, oral factor Xa inhibitor have
recently been completed.
The ENGAGE AF-TIMI 48 study in patients with
non-valvular atrial fibrillation at moderate-to-high
risk of stroke (N = 21,105; mean CHADS2 score
2.8), found that both high-dose edoxaban 60 mg
once daily and low-dose edoxaban 30 mg once daily
were non-inferior to well-controlled warfarin in the
prevention of stroke or systemic embolism, and were
also associated with significantly less bleeding and
death from a cardiovascular cause than warfarin.
The Hokusai-VTE study in patients with acute
symptomatic venous thromboembolism (VTE)
[N = 8,292] had a flexible treatment duration of
3–12 months and found that initial heparin/edoxaban
60 mg once daily was non-inferior to heparin/well-
controlled warfarin for the treatment and prevention
of recurrent VTE, with a significantly reduced risk of
bleeding.
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1 Introduction
Oral anticoagulant therapy is the cornerstone of stroke
prevention in patients with atrial fibrillation (AF) and,
overlapped with parenteral heparin, for the treatment and
prevention of venous thromboembolism (VTE). Oral anti-
coagulation with vitamin K antagonists (VKAs) such as
warfarin has been used for several decades but has a
number of limitations in long-term clinical use, including
variability in dose response; frequent, complex dose
adjustments; inadequate levels of anticoagulation;
increased risk of major bleeding or intracranial hemor-
rhage, particularly in the elderly; drug and food interac-
tions; a slow onset of action; a narrow therapeutic margin;
high discontinuation rates; and the need for coagulation
monitoring [1–3]. Obtaining the correct dose can often be
difficult and delayed at the initiation of VKA treatment.
Therefore pharmacogenetic studies recently assessed the
utility of genotype testing in choosing an initial dose of
VKA, showing that it offers only a limited to marginal
improvement versus standard of care [4–6]. In clinical
practice, it has been observed that between 40 and 50 % of
patients at risk do not receive treatment, in part because
VKAs are inconvenient for patients and physicians are
concerned about an increased bleeding risk [7–9].
The process of coagulation involves an amplifying
cascade in which one molecule of factor Xa can generate
approximately 1,000 molecules of thrombin [10]. Thus,
non-VKA oral anticoagulants (NOACs) have been devel-
oped that selectively target factor Xa (apixaban, edoxaban,
rivaroxaban and betrixaban) and also thrombin directly
(dabigatran). After decades of only one treatment option,
the NOACs have ushered in a new era in oral anticoagu-
lation. Several countries have approved the use of NOACs
for AF-related stroke prevention and for the prevention or
treatment of VTE. Although limited postmarketing sur-
veillance data were currently available, the 2012 European
Society of Cardiology (ESC) and 2012 Canadian Cardio-
vascular Society (CCS) AF guideline updates both included
a preference for NOACs in non-valvular AF (NVAF)
patients at risk of thromboembolism [11, 12]. The 2014
update of the American Heart Association (AHA)/Ameri-
can College of Cardiology (ACC)/Heart Rhythm Society
(HRS) AF guidelines recommended that in patients with
NVAF and prior stroke, transient ischemic attack or a
CHA2DS2-VASc score C2, treatment with an oral antico-
agulant such as warfarin [international normalized ratio
(INR) 2.0–3.0], dabigatran, rivaroxaban or apixaban was
recommended [13]. In patients who were not able to
maintain therapeutic INR on warfarin treatment, the AHA/
ACC/HRS guidelines recommended switching to an
NOAC [13]. In addition, the 2012 AHA/American Stroke
Association (ASA) AF guidelines recommended that
dabigatran, apixaban and rivaroxaban were suitable alter-
natives to warfarin in patients with NVAF, risk factors for
stroke or systemic embolism and without severe renal
impairment [14]. Regarding recommendations in patients
with VTE, the 2012 American College of Chest Physicians
(ACCP) VTE guidelines recommended initial treatment
with a parenteral heparin or fondaparinux, overlapped with
a VKA, dabigatran or rivaroxaban for anticoagulation
treatment [15].
The benefits of NOAC treatment have recently been
highlighted in meta-analyses of all four new oral agents
tested in phase III trials for stroke prevention in AF and the
treatment of acute VTE. In patients with AF (N = 71,683),
the NOACs reduced the risk of stroke or systemic embolic
events (SEEs) by 19 %, major bleeding by 14 % and
intracranial hemorrhage by 52 % compared with warfarin
[16]. In patients with acute VTE (N = 24,455), the NOACs
were non-inferior to VKAs in the treatment of VTE, and
were also associated with a significantly lower risk of
major bleeding than VKAs [17]. In addition to efficacy and
safety benefits, the NOACs offer important practical
advantages over VKA treatment, including a rapid onset of
action, no significant food interactions, lower potential for
drug interactions, and a predictable anticoagulant effect
that obviates the need for routine coagulation monitoring
[16].
The results of phase III clinical studies with edoxaban
have recently been reported for stroke prevention in
patients with AF and in the treatment of acute symptomatic
VTE. The objective of this review was to discuss these
findings and other key clinical and pharmacology studies
with edoxaban, and provide a perspective for edoxaban in
clinical practice.
2 Pharmacokinetic Properties
Clinical pharmacokinetic studies of edoxaban have shown
it has a predictable and consistent pharmacokinetic profile
(Table 1). In healthy subjects, edoxaban has predictable
pharmacokinetics that are closely related to dose. It is
rapidly absorbed and reaches peak plasma concentrations
(Cmax) in 1–2 h, with peak anti-factor Xa activity achieved
approximately 1.5 h after oral administration and remain-
ing above baseline levels for up to 24 h [18–20]. Edoxaban
has a half-life of approximately 10–14 h and its absolute
oral bioavailability is 62 % in healthy subjects [21, 22, 23].
Plasma protein binding of edoxaban is approximately
55 %, which is lower than with apixaban (87 %) and riv-
aroxaban (*90 %) (Table 1). Its relatively low protein
binding may be an important property of edoxaban because
of implications for patients on hemodialysis treatment;
hemodialysis did not affect protein binding, exposure or
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clearance of edoxaban (see Sect. 4.2.3) [24]. Food inter-
actions with VKAs are a limitation in the daily lives of
patients [1], but food intake, and also ethnicity and gender,
have no influence on edoxaban absorption, elimination,
Cmax, half-life or anti-factor Xa activity [25, 26].
Edoxaban undergoes biotransformation to various
metabolites and the most abundant of these (M4) is formed
through hydrolysis [27, 28]. Although the majority of an
edoxaban dose is excreted within 24 h, over 70 % is
excreted unchanged [28]. Edoxaban is eliminated in faeces
and urine, and a lower proportion of the administered dose
of edoxaban is eliminated via the kidneys (35 %) than with
dabigatran (85 %) and rivaroxaban (66 %) (Table 1) [2,
28].
Edoxaban 60 mg has also been assessed by Zahir et al.
during and 12 h after enoxaparin 1 mg/kg administration in
healthy volunteers (N = 40) [20]. This study found that the
pharmacokinetics of edoxaban [area under the plasma-
concentration curve (AUC); Cmax] were not affected by
enoxaparin, whether administered concomitantly or 12 h
apart. Edoxaban administered 12 h post-enoxaparin had
comparable or less inhibitory effects on thrombin genera-
tion compared with concomitant enoxaparin administra-
tion, but greater inhibitory effects compared with edoxaban
alone. There were no serious adverse events during the
study and edoxaban was well tolerated when administered
12 h post-enoxaparin [20].
A very limited proportion of edoxaban (\4 %) is
metabolized by cytochrome P450 and intestinal transport
of edoxaban, as with other NOACs, occurs through the
P-glycoprotein (P-gp) efflux transporter mechanism [28,
29]. The potential interaction between P-gp inhibitors and
edoxaban has therefore been characterized. The P-gp
inhibitor quinidine increases edoxaban exposure by
76.7 %, verapamil by 52.7 % and dronedarone by 84.5 %,
which are all over 1.5-fold, and therefore the dose of
edoxaban was reduced with concomitant treatment [22].
Amiodarone increases edoxaban exposure by 39.8 % and
therefore can be administered concomitantly without
edoxaban dose reduction [22]. Certain macrolide antibiot-
ics (erythromycin, azithromycin and clarithromycin), azole
antifungals (ketoconazole and itraconazole) and strong
P-gp inhibitors (ritonavir and cyclosporine) increase
edoxaban steady-state plasma concentrations, and it has
been recommended that systemic concomitant treatment
with edoxaban is contraindicated, which was outlined in
the ENGAGE AF-TIMI 48 study protocol [30]. Similarly, a
significant increase in rivaroxaban exposure has been
observed during concomitant treatment with ketoconazole
and ritonavir [31].
Concomitant therapy with aspirin has also been studied
with edoxaban, and it was found that a high-dose of aspirin
325 mg/day increased edoxaban exposure by 30 % and
Cmax by 34 %, whereas concomitant aspirin 100 mg/day
did not influence edoxaban pharmacokinetics [32]. Thus, in
phase III clinical trials with edoxaban, concomitant aspirin
was limited to doses B100 mg/day [30, 33].
3 Pharmacodynamic Properties
A phase I clinical study by Zafar et al. showed that
edoxaban causes substantial changes in INR, prothrombin
time (PT), anti-factor Xa activity and activated partial
thromboplastin time (aPTT). In particular, edoxaban pro-
longed aPTT by 1.3-fold, PT by 2.0-fold and INR by 2.0-
fold, all in a concentration-dependent manner [18]. In
addition, edoxaban 60 mg inhibits thrombin generation for
up to 24 h [20].
In an ex vivo study in healthy volunteers (N = 12), the
antithrombotic effects of edoxaban 60 mg once daily were
assessed under both venous and arterial flow conditions
[18]. This study found that under venous flow conditions
after 1.5 and 5 h, the thrombus was 28 and 21 % smaller
versus baseline, respectively (p \ 0.05). Similarly, under
arterial conditions, the corresponding reductions in
thrombus size were 26 and 17 % (p \ 0.05). Thrombin
generation also decreased by 28 % at 1.5 h and 10 % at
5 h, and was also associated with a decrease in size of the
acute platelet-rich thrombus [18]. Of note was that changes
in clotting parameters PT, INR and anti-factor Xa activity
correlated very closely with plasma edoxaban concentra-
tions (R2 = 0.79, 0.78 and 0.85, respectively) [18].
Also of interest is a study of edoxaban administered
24 h post warfarin therapy in healthy volunteers, which
found edoxaban was well tolerated, and transient increases
in PT, aPTT and anti-factor Xa activity returned to baseline
levels 24 h after edoxaban dosing [34]. In addition, a single
supratherapeutic dose of edoxaban 90 or 180 mg had no
effect on corrected QT interval versus placebo in healthy
volunteers, which suggested there is a low potential for
edoxaban to induce cardiac arrhythmias at therapeutic
doses (60 or 30 mg once daily) [35].
4 Clinical Trials
4.1 Phase I Clinical Trials
A dose-ranging study of edoxaban by Ogata et al. in
healthy volunteers assessed the safety of single doses of
edoxaban 10–150 mg once daily and multiple dosing of
edoxaban 90 and 120 mg once daily and edoxaban 60 mg
twice daily. All edoxaban doses were well tolerated and no
dose-dependent increase in treatment-emergent adverse
events (TEAEs) was observed [19]. After single doses of
1212 H. Bounameaux, A. J. Camm
edoxaban, TEAEs were reported in 17.4 % of subjects
compared with 9.5 % in the placebo group. No serious
adverse events were observed and 76.7 % of TEAEs were
mild. Similarly, after multiple administration of edoxaban,
77.0 % of TEAEs were mild and no serious adverse events
were reported [19]. The effects of edoxaban on clotting
parameters in healthy volunteers closely resembled those
determined ex vivo. Edoxaban plasma concentrations cor-
related with PT and aPTT after single administration
(R2 = 0.94 and 0.90, respectively) and multiple adminis-
tration (R2 = 0.97 and 0.89, respectively). Edoxaban had
dose-dependent effects on INR that reached a maximum
value of 3.5 and were reversible within 24–36 h [19].
4.2 Phase II Clinical Trials
4.2.1 Stroke Prevention in Atrial Fibrillation (AF)
The edoxaban phase II dose-ranging program in AF
patients was the most extensive performed among the
NOACs. A 12-week, parallel-group, multinational, dose-
ranging study by Weitz et al. in AF patients at risk of stroke
(N = 1,146), randomized patients to double-blind edox-
aban 30 mg once daily, 60 mg once daily, 30 mg twice
daily, 60 mg twice daily and open-label, dose-adjusted
warfarin (INR 2.0–3.0) [36]. The incidence of major and
clinically relevant non-major (CRNM) bleeding was sig-
nificantly higher in the twice-daily edoxaban 60 mg
(10.6 %; p = 0.002) and 30 mg (7.8 %; p = 0.029)
groups, compared with the warfarin group (3.2 %) (Fig. 1).
However, there was no significant difference in major
or CRNM bleeding between the warfarin and once-daily
edoxaban 60 and 30 mg groups [36]. Furthermore, trough
edoxaban concentrations (Cmin) were more closely linked
to bleeding rates than Cmax (Fig. 1). The higher edoxaban
trough concentrations seen with twice-daily versus once-
daily dosing may explain the higher bleeding incidence
with twice-daily dosing [36].
A similar 12-week, parallel-group, multinational, dose-
ranging study by Yamashita et al. in Asian patients with AF
(N = 536) randomized patients to double-blind edoxaban
30 mg, 45 mg, and 60 mg once daily and open-label, dose-
adjusted warfarin (INR 2.0–3.0) [37]. This study found
edoxaban 30, 45 and 60 mg once daily were associated
with comparable rates of all bleeding, major bleeding, and
major and CRNM bleeding compared with warfarin, and
there were no statistically significant differences between
groups. In addition, the Cmin of edoxaban was linked to
p=NS vs. warfarin
p=NS vs. warfarin
p=0.029 vs. warfarin
p=0.002 vs. warfarin
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Fig. 1 a Edoxaban plasma
exposure by dosing regimen;
b incidence of major and
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Reproduced from Weitz et al.
[36], with permission
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edoxaban dose and was higher in patients with body weight
B60 kg than in those [60 kg. The incidence of bleeding
events was also higher in patients who were B60 kg than
[60 kg in every treatment group and the difference was
most pronounced in the edoxaban 60 mg group, increasing
from 22.0 % ([60 kg subgroup) to 41.0 % (B60 kg sub-
group) [37]. In addition, a further study by Chung et al. in
Asian patients with AF (N = 235) compared double-blind
edoxaban 30 mg and 60 mg once daily with dose-adjusted
warfarin (INR 2.0–3.0) [38]. Edoxaban 60 mg and 30 mg
once daily were both associated with similar frequencies of
all bleeding, major bleeding and minor bleeding events,
which were all lower than with warfarin treatment. More-
over, in both the edoxaban 60 mg and 30 mg groups, the
incidence of all bleeding events in the subgroup of patients
with body weight B60 kg was higher than that in the
subgroup of those who weighed[60 kg [38]. Furthermore,
two open-label, dose-escalation studies performed in war-
farin-naı¨ve Japanese patients with AF, who were titrated
from edoxaban 5–30 mg (low-dose study, N = 24) and
from edoxaban 30–60 mg (high-dose study, N = 32),
confirmed the linear relationship between plasma edoxaban
concentrations, pharmacodynamic variables and reductions
in key coagulation biomarkers (D-dimer, thrombin-anti-
thrombin and prothrombin fragment F1?2) [39].
Prior to initiation of the phase III study in patients with
AF, a pooled analysis of phase I and phase II AF study
results assessed the population pharmacokinetics of edox-
aban, in order to identify factors that may affect exposure,
biomarkers that influence bleeding risk and aid dose
selection in the phase III study [40]. The data set included a
total of 15 clinical studies of 1,281 subjects comprising 494
healthy subjects and 787 patients with AF. The modeling
analyses found a statistically significant effect of patient
creatinine clearance on apparent edoxaban systemic
clearance (CL/F), and this was the most significant factor
to influence edoxaban disposition. Body weight and AF
status were found to have significant effects on apparent
volume of the central compartment (Vc/F). In addition,
concomitant P-gp inhibitor treatment had significant effects
on CL/F and edoxaban absorption rate constant (Ka), and
appeared to increase edoxaban relative bioavailability
(Frel). Modeling of edoxaban exposure in patients with
moderate renal impairment receiving strong P-gp inhibitors
found they could potentially increase the steady-state AUC
(AUCss) and Cmin (Cmin,ss) up to threefold, compared with
patients with normal renal function not taking strong P-gp
inhibitors. On the basis of similar and lower rates of
bleeding compared with warfarin, edoxaban 60 mg and
30 mg once daily, respectively, were recommended for
assessment in the phase III ENGAGE AF-TIMI 48 study in
patients with NVAF (electronic supplementary Fig. 1)
[41]. Taken together, this analysis and observations in the
phase II studies suggested that edoxaban dose reduction
(halving dose) be performed in patients taking a strong
P-gp inhibitor, patients with moderate renal impairment
(creatinine clearance 30–50 mL/min) or in patients with
body weight B60 kg [37, 38, 40].
4.2.2 Prevention of Venous Thromboembolism (VTE) After
Orthopedic Surgery
It is recommended that patients undergoing total hip or
knee arthroplasty surgery receive a minimum of
10–14 days of antithrombotic therapy because they are at
high risk of postoperative VTE. Treatment can reduce the
risk of deep-vein thrombosis (DVT) by 50–60 % and pul-
monary embolism (PE) by up to 66 % [42].
Edoxaban was investigated in a dose-ranging study by
Raskob et al. for the prevention of VTE in patients
undergoing elective hip replacement surgery (N = 903) in
the US [43]. This active-controlled study randomized
patients to edoxaban 15, 30, 60 or 90 mg once daily or
dalteparin once daily (initial dose 2,500 IU, followed by
5,000 IU), beginning 6–8 h postoperatively and continuing
for 7–10 days. The incidence of VTE was 28.2, 21.2, 15.2
and 10.6 % in patients receiving edoxaban 15, 30, 60 and
90 mg, respectively, compared with a significantly higher
rate of 43.8 % in the dalteparin group (p \ 0.005). In
addition, there was a statistically significant dose-response
for efficacy across the edoxaban dose groups for total and
major VTE (p \ 0.001) and comparable rates of clinically
relevant bleeding in all edoxaban and dalteparin groups
[43]. In addition, edoxaban 15 mg and 30 mg once daily
have been compared with subcutaneous enoxaparin for
VTE prevention, in a similar phase IIb, randomized, par-
allel-group study of Japanese patients undergoing total hip
replacement surgery (N = 264) [44]. Treatment was
administered for 11–14 days after surgery and this study
found no difference in the incidence of thromboembolic
events, which were 3.8, 2.8 and 4.1 % in the edoxaban 15
and 30 mg and enoxaparin groups, respectively. There was
also no difference in major or CRNM bleeding between the
treatment groups [44].
With regard to the prevention of VTE following total
knee replacement surgery, a phase IIb, dose-ranging, ran-
domized, placebo-controlled study in Japanese patients
(N = 523) compared edoxaban 5, 15, 30 and 60 mg once
daily with placebo for 11–14 days after surgery [45]. This
study did not use low-molecular weight heparin or fonda-
parinux as a control treatment because they were not
approved in Japan at the time of study initiation. Edoxaban
treatment resulted in a dose-dependent and significant
reduction in VTE incidences, which were 29.5, 26.1, 12.5
and 9.1 % in the edoxaban 5, 15, 30 and 60 mg groups,
respectively, compared with 48.3 % in the placebo group
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(p \ 0.001 for all edoxaban doses vs. placebo). There was
also no significant difference in major bleeding or major or
CRNM bleeding rates between any of the edoxaban dose
groups and placebo [45].
The phase II studies of edoxaban for the prevention of
VTE following total hip or knee replacement surgery
found that edoxaban is effective in preventing VTE and is
well tolerated, with a bleeding incidence similar to pla-
cebo after knee replacement surgery and also to enoxap-
arin or dalteparin after hip replacement surgery [43–45].
Subsequent Japanese phase III studies for the prevention
of VTE following orthopedic surgery assessed the edox-
aban 30 mg once-daily dose on the basis of the efficacy,
safety and bleeding findings in the phase II study
program.
4.2.3 Patients with Renal Impairment
In view of the role of the kidneys in the elimination of
edoxaban, Koretsune et al. performed an open-label,
8-week study in patients with AF and renal impairment
(N = 93) [46]. They compared edoxaban 15 mg once daily
in patients with severe renal impairment with edoxaban
60 mg and 30 mg once daily in patients with normal renal
function or mild renal impairment. Bleeding events
occurred at a similar rate in each group and no major
bleeding events were seen in any group. Median PT ratios
were also similar in the edoxaban 15 mg (severe renal
impairment) and 30 mg (normal renal function or mild
impairment) groups for up to 8 h after drug administration.
Therefore, this preliminary study suggests that edoxaban
15 mg once daily may be an appropriate dose in patients
with AF and severe renal impairment [46].
A similar open-label study was conducted in Japanese
patients with renal impairment (N = 80) who were
undergoing lower-limb orthopedic surgery [47]. The safety
and pharmacokinetics of edoxaban 15 mg once daily in
patients with severe renal impairment were compared with
edoxaban 30 mg once daily in patients with mild renal
impairment and fondaparinux 1.5 mg in patients with
severe renal impairment. By day 7 of treatment, edoxaban
plasma concentrations overlapped between patients with
severe and mild renal impairment who received edoxaban
15 and 30 mg, respectively. Bleeding events occurred in 6
(20.7 %), 10 (33.3 %) and 8 (40.0 %) patients in the
edoxaban 15 mg, edoxaban 30 mg, and fondaparinux
1.5 mg groups, respectively, but no major bleeding events
occurred in any group. These results suggest that edoxaban
15 mg once daily may be a suitable dose in patients
undergoing orthopedic surgery who have severe renal
impairment [47].
It is important to understand the safety and appropriate
dose of a new antithrombotic agent such as edoxaban in
patients undergoing hemodialysis treatment. Edoxaban
has a plasma protein binding of 55 % and renal clearance
of 35 % of administered dose and may be received by
patients with severe renal impairment (with or without
hemodialysis) [19]. An initial open-label study of patients
with end-stage renal disease undergoing dialysis (N = 10)
compared the safety and pharmacokinetics of edoxaban
15 mg dosed 2 h prior to a 4 h hemodialysis session, with
a day without hemodialysis [24]. When administered
without and with hemodialysis, edoxaban exposures were
comparable with an AUC0–? of 692 ± 150 and
676 ± 221 ng  h/mL, respectively. Hemodialysis also
had minimal effects on the clearance of edoxaban, with
total clearance values of 24 and 23 L/h with and without
hemodialysis. The plasma protein binding of edoxaban
was also similar with and without hemodialysis and ran-
ged from 60 to 63 %. This study therefore indicated that
hemodialysis has a minimal effect on the clearance of
edoxaban, is not an effective mechanism of removal of
edoxaban from the bloodstream, and additional dose
reduction of edoxaban, to compensate for potential drug
loss via hemodialysis, may not be necessary before he-
modialysis [24].
4.3 Phase III Clinical Trials
A large number of phase III clinical studies have been
performed with the NOACs. The studies performed in
patients with AF, acute VTE, and undergoing orthopedic
surgery are summarized in Tables 2, 3 and 4, respectively.
In particular, studies with edoxaban have been recently
completed in stroke prevention in patients with NVAF and
also in the treatment of symptomatic VTE. Both these
studies were specifically designed to simulate clinical
practice as much as possible, with dose reduction at and
after randomization, frequent INR monitoring and feed-
back, assessment of time in (INR) therapeutic range (TTR),
comprehensive transition strategies at study end, and a
flexible treatment duration in the Hokusai-VTE study [30,
33].
4.3.1 Stroke Prevention in AF
ENGAGE AF-TIMI 48 was a randomized, double-blind,
double-dummy, international, non-inferiority study that
compared two once-daily edoxaban regimens with well-
controlled warfarin treatment (electronic supplementary
Fig. 1, [48]). The primary efficacy endpoint was stroke or
SEE, and the primary safety outcome was major bleeding.
A total of 21,105 patients with NVAF (CHADS2 score
C2) were randomized to edoxaban 60 mg once daily
(high-dose regimen), 30 mg once daily (low-dose regi-
men) and dose-adjusted warfarin (INR 2.0–3.0). The
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overall mean CHADS2 score was 2.8; therefore, patients
in ENGAGE AF-TIMI 48 were at moderate-to-high risk
of stroke or systemic embolism. The demographic and
clinical characteristics of the treatment groups were well
balanced at baseline and the median duration of treatment
exposure was 907 days, excluding interruptions; the
median follow-up was 1,022 days (2.8 years). The criteria
for dose reduction were concomitant treatment with a
strong P-gp inhibitor (verapamil, quinidine or droneda-
rone), body weight B60 kg or creatinine clearance
30–50 mL/min. Patients in the high-dose group were
reduced from edoxaban 60 mg to 30 mg once daily and
those in the low-dose group were reduced from edoxaban
30 mg to 15 mg once daily in a double-blind manner. A
total of 5,330 patients (25.3 %) received a reduced dose
of edoxaban or matching placebo at randomization. After
randomization, dose reduction occurred in 7.1 % of
patients. There were also significantly fewer drug inter-
ruptions in both edoxaban groups compared with warfarin
(p \ 0.001 for both comparisons). The median TTR of
the warfarin group was 68.4 % (interquartile range
56.5–77.4 %) (Table 2), indicating patients in the warfa-
rin group received optimal treatment and acted as an
effective active comparator for edoxaban. At the end of
the trial, patients made the transition to open-label oral
anticoagulant therapy with the use of a detailed transition
plan and frequent monitoring and INR assessment for
30 days [30].
The primary efficacy outcome of stroke or SEE in the
modified intention-to-treat (mITT) on-treatment analysis
occurred at a rate of 1.50 % per year in the well-controlled
warfarin group, 1.18 % per year in the high-dose edoxaban
60 mg once-daily group (p \ 0.001 for non-inferiority;
p = 0.02 for superiority) and 1.61 % per year in the low-
dose edoxaban 30 mg once-daily group (p = 0.005 for
non-inferiority; p-value not significant for superiority)
(Fig. 2a) [30]. In the overall ITT superiority analysis there
was also a trend favoring high-dose edoxaban (1.57 %)
versus warfarin (1.80 %; p = 0.08 for superiority), while
the trend was unfavorable for the low-dose edoxaban group
(2.04 %) versus warfarin (p = 0.10 for superiority). The
rates of hemorrhagic stroke in the high-dose and low-dose
edoxaban groups (0.26 and 0.16 %, respectively) were
statistically significantly lower than with warfarin (0.47 %;
p \ 0.001). With regard to ischemic stroke, the edoxaban
high-dose group (1.25 %) was not significantly different to
warfarin (1.25 %; p = 0.97 vs. warfarin), while the low-
dose group (1.77 %) had a statistically significantly higher
rate than the warfarin group (p \ 0.001 vs. warfarin).
Among patients who were dose reduced, there was no
difference in primary events versus patients not dose
reduced in either the high-dose group (p = 0.97 for inter-
action) or the low-dose group (p = 0.74 for interaction)
[30]. In addition, death from a cardiovascular cause
occurred at a rate of 3.17 % in the warfarin group and at a
significantly lower rate in both the high-dose edoxaban
group (2.74 %; hazard ratio [HR] 0.86 [95 % confidence
interval [CI]: 0.77–0.97]; p = 0.013) and low-dose edox-
aban group (2.71 %; HR 0.85 [95 % CI: 0.76–0.96];
p = 0.008]). There were also no differences observed in
the rate of myocardial infarction between high-dose
edoxaban and warfarin (0.70 % vs. 0.75 %; HR 0.94 [95 %
CI: 0.74–1.19]; p = 0.60) or between low-dose edoxaban
and warfarin (0.89 % vs. 0.75 %; HR 1.19 [95 % CI:
0.95–1.49]; p = 0.13), which indicated the risk of myo-
cardial infarction was not elevated during edoxaban treat-
ment [30].
The ENGAGE AF-TIMI 48 study found a statistically
significantly reduced rate of major bleeding between the
high-dose (2.75 %) and low-dose (1.61 %) edoxaban
groups versus well-controlled warfarin (3.43 %;
p \ 0.001 for both groups) (Fig. 2b). With regard to
intracranial hemorrhage, the high-dose (0.39 %) and low-
dose groups (0.26 %) both had significantly lower rates
than the warfarin group (0.85 %; p \ 0.001 for both dose
comparisons). Both edoxaban regimens also had statisti-
cally significantly lower rates of fatal bleeding, life-
threatening bleeding, major or CRNM bleeding and any
overt bleeding than with warfarin (p B 0.01 for all com-
parisons). Compared with warfarin (0.82 %), the low-dose
edoxaban group had a significantly lower rate of gastro-
intestinal bleeding (1.23 %; p \ 0.001 vs. warfarin),
while a statistically higher rate was observed in the high-
dose edoxaban group (1.51 %; p = 0.03 vs. warfarin).
With regard to patients who were dose-reduced, the rate
of major bleeding was significantly lower compared with
patients not dose-reduced in the high-dose (p = 0.02 for
interaction) and low-dose (p \ 0.01 for interaction) e-
doxaban groups [30]. In addition, both the high-dose and
low-dose edoxaban groups had a similar frequency of any
or drug-related adverse events compared with the warfarin
group. Regarding hepatic safety, both the high-dose and
low-dose edoxaban groups also had a similar frequency of
aspartate aminotransferase (AST) or alanine aminotrans-
ferase (ALT) C39 and total bilirubin C29 upper limit of
normal versus the warfarin group. A similar pattern was
also observed with the frequency of adjudicated hepato-
cellular injury, cholestasis and patients who satisfied Hy’s
Law criteria. Therefore, treatment with either high-dose or
low-dose edoxaban was not associated with hepatic
adverse events in patients with NVAF [30]. Overall, the
efficacy and safety results with edoxaban in ENGAGE
AF-TIMI 48 showed it was non-inferior to warfarin for
stroke and SEE prevention in NVAF and was associated
with a significantly lower risk of bleeding and death from
a cardiovascular cause [30].
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4.3.2 Treatment of Symptomatic VTE
Hokusai-VTE was the largest study ever conducted in
acute symptomatic VTE, with 8,292 patients randomized
internationally. The study had a randomized, double-blind,
double-dummy, parallel-group, non-inferiority design, a
flexible treatment duration of 3–12 months and primary
analysis of all patients at 12 months (electronic supple-
mentary Fig. 2). Hokusai-VTE compared the efficacy and
safety of an enoxaparin/unfractionated heparin lead-in
followed by edoxaban 60 mg once daily versus standard
of care [enoxaparin/unfractionated heparin lead-in fol-
lowed by warfarin (INR 2.0–3.0)] in the treatment of
symptomatic VTE, with a primary efficacy outcome of
recurrent symptomatic VTE and a primary safety outcome
of major or CRNM bleeding [33]. Patients in the edox-
aban group who qualified for dose reduction (creatinine
clearance 30–50 mL/min, body weight B60 kg or con-
comitant administration of strong P-gp inhibitors) were
switched to edoxaban 30 mg once daily in a double-blind
manner. At randomization, approximately 17 % of
patients in each treatment group were dose-reduced and
approximately 65 % of patients had an unprovoked VTE
index event, who were at a particularly high risk of
recurrent disease [15]. Other baseline characteristics of
patients in each treatment group were also similar.
Approximately 40 % of patients randomized in Hokusai-
VTE had PE, of those 46 % had extensive PE (defined as
involvement of multiple lobes with 25 % or more of the
entire vasculature), and 42 % of DVT patients were
classified as extensive (defined as an event in which the
most proximal site was the common femoral or iliac
vein). Hokusai-VTE had a flexible treatment duration:
40 % of patients received treatment for the entire duration
of 12 months, while over 61 % received treatment for
over 6 months. In the warfarin group, the mean TTR was
63.5 %, indicating that these patients were well-controlled
in Hokusai-VTE [33].
Hokusai-VTE demonstrated that edoxaban 60 mg once
daily after initial treatment with heparin was non-inferior to
well-controlled standard therapy and caused significantly
less bleeding in a broad range of patients with VTE. The
rate of symptomatic recurrent VTE was 3.2 % per year in
the edoxaban group, compared with 3.5 % per year in the
standard therapy group (p \ 0.001 for non-inferiority)
(Fig. 2a). Edoxaban 60 mg once daily was also associated
with significantly fewer major or CRNM bleeding events
compared with well-controlled standard therapy (8.5 % per
year vs. 10.3 % per year, p = 0.004 for superiority)
(Fig. 2b) [33]. Edoxaban was effective across a broad
range of DVT and PE patients and over a flexible treatment
duration of 3–12 months. Compared with VTE recurrence
rates in the overall analysis of patients treated withT
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edoxaban or warfarin for 3–12 months, those observed in
the on-treatment analysis of patients treated for 12 months
were lower in both the edoxaban (3.2 % vs. 1.6 % per year)
and warfarin (3.5 % vs. 1.9 % per year) arms, with edox-
aban also non-inferior to warfarin in the on-treatment
analysis (p \ 0.001 for non-inferiority). With regard to
patients with a DVT index event, recurrent VTE was
observed in approximately 3.4 % and 3.3 % of the edox-
aban and warfarin groups [HR 1.02 (0.75–1.38)], respec-
tively. In patients with a PE index event, recurrent VTE
was recorded in 2.8 % and 3.9 % of the edoxaban and
warfarin groups, respectively, with no statistically signifi-
cant difference found [HR 0.75 (0.50–1.06)]. Edoxaban
also demonstrated robust efficacy versus warfarin (3.3 %
vs. 6.2 % per year) in the subgroup of PE patients with
evidence of right ventricular dysfunction N-terminal of the
prohormone brain natriuretic peptide (NT-proBNP level
C500 pg/mL), which was supported by an analysis in a
large subset of patients assessed by computed tomography
(n = 1,002). Among patients who were dose-reduced to
edoxaban 30 mg once daily, the rates of VTE recurrence,
major bleeding and major or CRNM bleeding were all
lower in the edoxaban group than in the warfarin group,
suggesting that patient-specific dosing of edoxaban main-
tains efficacy and safety [33]. The rate of serious adverse
events, serious adverse events leading to discontinuation
and adverse events occurring on treatment were similar in
the edoxaban and warfarin groups. Regarding hepatic
safety, the edoxaban group had a similar frequency of ALT
C39 or C59 upper limit of normal, ALT or AST C39 and
total bilirubin C29 upper limit of normal, as well as
patients who satisfied Hy’s Law criteria compared with the
warfarin group. Therefore, treatment with edoxaban was
not associated with hepatic adverse events in patients with
symptomatic VTE [33].
In addition, a pre-specified post hoc analysis of patients
with active or a history of cancer randomized in Hokusai-
VTE (n = 771) assessed the efficacy and safety of
edoxaban in this large subgroup that comprised 9.3 %
of patients [49]. Recurrent VTE occurred in 3.7 % of
patients given edoxaban and 7.1 % who received warfa-
rin. Major or CRNM bleeding occurred in 12.4 % of the
edoxaban group and a higher proportion of 18.8 % of the
warfarin group. This analysis suggested that edoxaban
was as effective, and possibly more effective, than war-
farin in cancer patients with VTE, and may potentially
reduce bleeding versus warfarin in such patients [49].
Overall, the Hokusai-VTE study, which had a flexible
treatment duration to simulate routine clinical practice as
much as possible, indicated edoxaban was an effective,
well tolerated treatment, with a lower risk of bleeding
than standard warfarin therapy, in a broad spectrum of
acute symptomatic VTE patients [33].T
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4.3.3 Prevention of VTE After Orthopedic Surgery
A comprehensive phase III clinical program comprising the
randomized, double-blind, double-dummy STARS E-3,
STARS J-4 and STARS J-5 studies of edoxaban, estab-
lished its efficacy and safety in the prevention of VTE after
orthopedic surgery. The STARS E-3 trial in patients
undergoing total knee replacement surgery randomized
patients (N = 716) to edoxaban 30 mg once daily or sub-
cutaneous enoxaparin 20 mg every 12 h, for 11–14 days
[50]. The primary efficacy endpoint was symptomatic
VTE. VTE events occurred in 13.9 % of the enoxaparin
group and in 7.4 % of patients receiving edoxaban treat-
ment, which was non-inferior (p \ 0.001) and superior
(p = 0.010) to enoxaparin treatment. Major bleeding
occurred in 1.1 % of the edoxaban group and 0.3 % of the
enoxaparin group (p = 0.373 vs. edoxaban), and major and
CRNM bleeding occurred in 6.2 % of patients who
received edoxaban and 3.7 % of the enoxaparin group
(p = 0.129 vs. edoxaban). The STARS E-3 trial therefore
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Fig. 2 Kaplan–Meier curves
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ENGAGE AF-TIMI 48.
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demonstrated edoxaban was superior to enoxaparin in the
prevention of VTE after total knee replacement surgery,
without a significant increase in bleeding rates [50].
The STARS J-5 study had an analogous design to
STARS E-3, but was conducted in patients (N = 610)
undergoing total hip replacement surgery [51]. VTE events
occurred in 6.9 % of patients who received enoxaparin and
2.4 % of patients who received edoxaban, which was non-
inferior (p \ 0.001) and superior (p = 0.0157) to enoxap-
arin. Major and CRNM bleeding occurred in 2.6 % of
patients who received edoxaban and 3.7 % of the enox-
aparin group (p = 0.475 vs. edoxaban), while major
bleeding occurred in 0.7 % of the edoxaban group and
2.0 % of the enoxaparin group. The STARS J-5 trial
therefore demonstrated edoxaban was superior to enoxap-
arin in the prevention of VTE after total hip replacement
surgery and was associated with a similar risk of bleeding
[51] (Fig. 3).
STARS J-4 was a multicenter, open-label, safety study
in Japanese patients (N = 92) undergoing hip-fracture
surgery, in which patients were randomized to edoxaban
30 mg once daily or subcutaneous enoxaparin 2,000 IU
every 12 h, for 11–14 days [52]. The incidence of major
and CRNM bleeding was 3.4 % in the edoxaban group and
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Hokusai-VTE. a recurrence of
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bleeding. Edoxaban dose:
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weight B60 kg, or while taking
a strong P-glycoprotein
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6.9 % in the enoxaparin group, while any bleeding event
occurred in 25.4 and 17.2 % of patients, respectively.
There was one episode of major bleeding in each group and
the rate of asymptomatic thromboembolic events was
6.5 % in the edoxaban group and 3.7 % in the enoxaparin
group, with no symptomatic events observed. Edoxaban
therefore demonstrated similar safety and efficacy to en-
oxaparin in Japanese patients undergoing hip-fracture sur-
gery [52]. Overall, the STARS study program
demonstrated that edoxaban was more effective than en-
oxaparin in the prevention of VTE following total hip or
knee replacement surgery and was associated with a similar
risk of bleeding. The STARS studies supported regulatory
approval of edoxaban 30 mg once daily for the prevention
of VTE following orthopedic surgery in Japan in 2011.
4.4 Phase IV Postmarketing Surveillance
4.4.1 Prevention of VTE After Orthopedic Surgery
in Japan
A postmarketing safety analysis of patients treated with
edoxaban 30 mg once daily for the prevention of VTE after
orthopedic surgery has been conducted in Japan [53]. This
study assessed the first 6 months of postmarketing expe-
rience, during which approximately 20,000 patients
received edoxaban. The mean age of patients was
74.2 years, mean weight was 59.4 kg, and approximately
70 % were female. A total of 67 adverse events (51
bleeding events) were observed in 56 patients (0.3 % of
population). Therefore, this postmarketing analysis found
no safety signals that were not previously observed in
clinical studies with edoxaban 30 mg once daily [53].
5 Management of Bleeding Complications
Guidance on the emergency reversal of anticoagulant
effects from NOAC treatment has recently been formulated
by a group of experts participating in the Thrombosis and
Hemostasis Summit of North America [54]. In the case of
overdose, activated charcoal may be administered within
3 h of NOAC dosing to reduce gastrointestinal absorption.
For patients who experience major bleeding, treatment
discontinuation and supportive care were recommended
[54].
At present there is no specific antidote available for the
anticoagulant effects of edoxaban, but studies of potential
agents are currently underway. However, initial preclinical
studies with activated recombinant human factor VII
(rhFVIIa), a prothrombin complex concentrate (PCC,
PPSB-HT) and a prothrombin complex concentrate with
activated factor VII (aPCC; FEIBA), found they can
significantly reduce the changes in PT caused by edoxaban
in a concentration-dependent manner [55]. It has also been
suggested that a recombinant factor Xa protein (andexa-
net alfa, PRT4445), which is catalytically inactive and does
not inhibit factor Xa, may be a potential reversal agent for
factor Xa inhibition. Preliminary results with this agent
suggest a dose-dependent reversal of factor Xa inhibition
with rivaroxaban [56]. A phase II proof-of-concept study in
healthy volunteers to evaluate the safety, tolerability,
pharmacokinetics and pharmacodynamics of andexa-
net alfa after dosing of a direct or indirect factor Xa
inhibitor is currently ongoing (NCT01758432). Recent
results from this ongoing clinical trial demonstrate that
andexanet alfa is able to dose-dependently, partially
reverse the anticoagulant effects of rivaroxaban and apix-
aban, as assessed by pharmacodynamic markers, in healthy
subjects [57]. In addition, a synthetic small molecule
(PER977) has been designed and synthesized for the
reversal of anticoagulation with NOACs. Preliminary
in vitro studies with PER977 and assessment of rat-tail
bleeding models have shown that it directly and specifi-
cally binds the NOACs to reverse anticoagulant activity.
PER977 reverses the anticoagulant effects of edoxaban
within 20 minutes after administration. It also exhibits no
binding to any human plasma coagulation factors or albu-
min and has shown no procoagulant properties [58, 59]. A
first-in-human clinical trial to assess the safety and efficacy
of PER977 3 h after administration of edoxaban 60 mg in
healthy human volunteers is ongoing (NCT01826266).
6 Discussion
The prevention of thromboembolic events is a significant
global healthcare issue. Although VKAs have been used
for several decades and are effective in preventing throm-
boembolic events, they have considerable limitations in
clinical practice [1]. Thus, the NOACs, including edox-
aban, were developed to provide effective, convenient
anticoagulation treatment, with reduced bleeding risk
compared with warfarin.
The multinational edoxaban phase III clinical studies
ENGAGE AF-TIMI 48 and Hokusai-VTE were completed
in 2013. ENGAGE AF-TIMI 48 compared a high-dose and
low-dose edoxaban dosing regimen with warfarin in
patients with AF at moderate-to-high risk of stroke. Both
high-dose and low-dose edoxaban regimens were non-
inferior to warfarin for stroke prevention, and also associ-
ated with a significantly lower rate of bleeding and
cardiovascular mortality [30]. Regarding efficacy obser-
vations in the high-dose edoxaban arm, a reduction in risk
of 21 % for stroke or SEE, 46 % for hemorrhagic stroke,
14 % for cardiovascular mortality and 13 % for intracranial
1226 H. Bounameaux, A. J. Camm
hemorrhage was found compared with well-controlled
warfarin. In terms of safety, a reduction in risk of 20 % for
major bleeding, 45 % for fatal bleeding and 53 % for
intracranial bleeding was observed in the high-dose edox-
aban arm versus well-controlled warfarin [30]. The
Hokusai-VTE study in a broad spectrum of patients with
acute symptomatic VTE compared initial heparin and e-
doxaban 60 mg once daily with initial heparin and warfarin
treatment for a flexible treatment duration of 3–12 months.
Edoxaban was non-inferior to warfarin in the prevention of
recurrent VTE and was also associated with a significantly
lower bleeding rate than warfarin [33]. The risk of recur-
rent VTE was lowered by 11 %, major or CRNM bleeding
by 19 % and any bleeding by 18 % in the edoxaban group
compared with warfarin [33]. In addition, Hokusai-VTE
showed that the duration of treatment for symptomatic
VTE is an important factor to consider in every patient to
balance the risk of recurrence with bleeding. The rate of
events was lower in the on-treatment analysis of patients
who remained on edoxaban or warfarin treatment for
12 months compared with the overall analysis of patients
who were treated for 3–12 months. As a large proportion of
patients had extensive PE, these data may support the
continuation of therapy [33]. It was notable that the
Hokusai-VTE study included a substantial subpopulation
with cancer and, in this subgroup, patients who received
edoxaban had a lower rate of VTE recurrence and signifi-
cantly lower rate of bleeding than those in the warfarin
group [49]. Dose reduction was performed throughout
ENGAGE AF-TIMI 48 and Hokusai-VTE in patients at
risk of overexposure (creatinine clearance 30–50 mL/min,
body weight B60 kg or concomitant treatment with a
strong P-gp inhibitor). Efficacy was maintained in patients
who were dose reduced in both studies, and in ENGAGE
AF-TIMI 48 a significantly lower rate of bleeding was
observed compared with patients who were not dose-
reduced [30, 33]. Therefore, patient-tailored dosing of
edoxaban may provide an effective option in clinical
practice, which could also help lower the risk of bleeding.
The ENGAGE AF-TIMI 48 and Hokusai-VTE studies
build upon the STARS phase III clinical program in Japan,
in which edoxaban was superior to enoxaparin in the pre-
vention of VTE after orthopedic surgery, with a similar risk
of bleeding [51, 60]. Edoxaban 30 mg once daily is cur-
rently approved for the prevention of VTE after orthopedic
surgery in Japan, and postmarketing surveillance data has
not found any unforeseen safety signals and a limited
number of bleeding events with edoxaban [53]. Marketing
authorization for once-daily edoxaban for stroke preven-
tion in AF and the treatment and prevention of recurrence
of VTE in the US and EU was requested in January 2014.
A major limitation of VKA treatment is an increased
risk of bleeding. In patients with AF, VKA therapy
increases the risk of major bleeding and intracranial hem-
orrhage by 0.3–0.5 % and 0.2 % per year, respectively [3].
This limits its use because physicians can be reluctant to
prescribe warfarin to the elderly or patients at heightened
risk of bleeding, such as those with a history of falls, and
intracranial or gastrointestinal hemorrhage [61]. In clinical
practice, bleeding events are also a reason to stop antico-
agulant treatment [54]. Therefore, the observation of
reduced bleeding with edoxaban versus VKA treatment in
a broad spectrum of patients with acute VTE, as well as
patients with NVAF at moderate-to-high risk of stroke,
may be an important benefit for patients. In addition,
edoxaban treatment has the convenience of once-daily oral
administration, which may help ensure patient adherence to
treatment.
Edoxaban has a predictable pharmacokinetic profile and
dose response that allows treatment without the need for
regular coagulation monitoring, which has been a major
limitation to VKA treatment for decades [1, 18, 19].
However, at present there is no validated test to assess the
antithrombotic effect of any of the NOACs. The avail-
ability of such a test might be helpful in emergency situ-
ations such as serious bleeding and surgery, or special
clinical situations such as suspected overdose, patients with
renal/hepatic insufficiency or with uncertainty about
NOAC administration. The management of bleeding
complications with an NOAC such as edoxaban would also
require a rapid and safe reversal agent for factor Xa inhi-
bition. In this regard, a potential agent (PER977) has
demonstrated effective reversal of factor Xa inhibition
in vitro and in a rat-tail bleeding model [58, 59]. Currently,
PER977 is being assessed after edoxaban administration in
a clinical study (NCT01826266) and andexanet alfa is also
being investigated after administration of various NOACs
(NCT01758432). The availability of an effective reversal
agent at the time of edoxaban regulatory approval in the
US, EU and Japan would prove helpful in emergency sit-
uations where rapid reversal of anticoagulation is required.
The phase III clinical studies with dabigatran, rivarox-
aban, apixaban and edoxaban for stroke prevention in
patients with AF and also for prevention of recurrence in
patients with acute VTE have recently been assessed in two
meta-analyses [16, 17]. With regard to stroke prevention in
patients with AF, the NOACs overall provided significant
reductions in the rate of stroke or systemic embolism,
hemorrhagic stroke, all-cause mortality and intracranial
hemorrhage compared with warfarin. In addition, the
overall relative efficacy and safety of the NOACs was
consistent across a wide range of patients with AF,
including those with diabetes, moderate and mild renal
impairment, CHADS2 score 3–6 and center-based
TTR \66 %. A direct comparison of the phase III studies
is difficult because each had patients with a different mean
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CHADS2 score and other major differences in design, such
as the open-label warfarin, blinded dabigatran RE-LY trial
and randomized, double-blind, double-dummy ENGAGE
AF-TIMI 48 study (Table 2) [16]. In the treatment of
patients with acute VTE, the NOACs overall had compa-
rable efficacy to VKA therapy in the prevention of VTE
recurrence, fatal PE and in the rate of all-cause mortality.
However, benefits with NOAC therapy in VTE were
observed with significantly lower bleeding rates, as in
patients with AF [17]. Taken together, the NOACs provide
important benefits in safety and bleeding compared with
VKA treatment, and offer new options for the prevention of
thromboembolic events.
7 Conclusions
Edoxaban once daily is a well-tolerated inhibitor of factor
Xa that has demonstrated non-inferior efficacy together
with a superior bleeding profile compared with an opti-
mized standard of care for both stroke prevention in
patients with NVAF and the treatment and prevention of
symptomatic recurrent VTE. Edoxaban also offers several
additional benefits over traditional VKA therapy for
stroke prevention in patients with NVAF, of which sig-
nificant reductions in hemorrhagic stroke, intracranial
bleeding and cardiovascular mortality, and the absence of
laboratory monitoring may be of key importance to
patients. Marketing authorization for once-daily edoxaban
has been requested in the US, EU and Japan for stroke
prevention in patients with NVAF and the treatment and
prevention of recurrence of VTE. Given the ENGAGE
AF-TIMI 48 and Hokusai-VTE studies were designed to
simulate clinical practice and showed edoxaban once daily
was effective and safe in two large populations of patients
at moderate-to-high risk of thromboembolic events,
edoxaban may prove to be a key addition to antithrom-
botic therapy.
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